2024 Spring Scanner: Unveiling the Storm - Navigating the Thyroid Storm after Radioiodine Therapy
Release Date: May 1, 2024
Expiration Date: May 31, 2027
SNMMI/ACNM Members: $0
Non-Members: $20
Continuing Education Credit Information
ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 1.0 SAMs have been awarded for this activity.
AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. SNMMI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Target Audience
The Life Long Learning and Self-Assessment activity is designed for all nuclear medicine physicians and radiologists.
Objectives
Release Date: May 1, 2024
Expiration Date: May 31, 2027
SNMMI/ACNM Members: $0
Non-Members: $20
Continuing Education Credit Information
ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 1.0 SAMs have been awarded for this activity.
AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. SNMMI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Target Audience
The Life Long Learning and Self-Assessment activity is designed for all nuclear medicine physicians and radiologists.
Objectives
• Identification of high-risk patients before radioiodine therapy - Elderly, severe thyrotoxicosis or prolonged thyrotoxic phase and those with underlying cardiovascular or cerebrovascular disease.
• The patient should be rendered euthyroid by the use of anti-thyroid drugs for two weeks to two months before radioiodine therapy.
• A three-day withdrawal of an anti-thyroid drug is sufficient for radioiodine uptake.
• The patient should be rendered euthyroid by the use of anti-thyroid drugs for two weeks to two months before radioiodine therapy.
• A three-day withdrawal of an anti-thyroid drug is sufficient for radioiodine uptake.
Author
Dr. Yogita Khandelwal
Senior Resident, Department of Nuclear Medicine
AIIMS, New Delhi, India
Financial Disclosure
In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the speaker has indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.
Contact Information
For questions please contact Lisa Dickinson, Associate Director of Education at ldickinson@snmmi.org or 703-652-6783.
